The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Most Medicare Part D plans include coverage for Repatha, though specific coverage details can vary among plans. Out-of-pocket costs for Repatha under Medicare Part D typically average around $49 per ...

You know the drill by now. You're sitting in the purgatory of the service center waiting room. Precisely 63 minutes into your wait, the service adviser walks out with a clipboard and calls your name — ...

If I wasn’t sleeping, I was crying. I couldn’t think straight anymore. My adult daughter helped me realize Repatha was causing my depression. I slowly started feeling better after stopping the ...

Editor’s note: This is a corollary to an article by the same author on instances when a hydraulic press might be the best option — “Hydraulic vs. Electric Injection Molding Machines: When Energy ...

What we're doing is that I'll be showing you how I usually clean intake valve deposits on gasoline direct injection engines on the DIY, efficiently, and with consistent good results, and then along ...

We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently discussed. Amgen Inc. ...

Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...

Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more. Got a confidential news tip?

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions similar to those observed with existing injectables. The results from two phase ...

(Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack or stroke, according to results ...